The ARIES trial compares an early versus a late start for a Treat-and-Extend (T&E) regimen, an increasingly popular approach to treatment worldwide, for wet or neovascular age-related macular degeneration (AMD). Professor Paul Mitchell gives an overview of the study, and then goes on to discuss wet AMD and the differences to dry AMD, the specifics and benefits of the T&E regimen and the importance of dosing frequency in real-world cases.
1. Could you please summarise the study design, rationale and aims of the ongoing ARIES clinical trial? What is unique with the ARIES study? (0:11)
2. What is wet age-related macular degeneration (also known as neovascular AMD), and how does it differ in pathogenesis and manifestation from dry AMD? (1:46)
3. What is aflibercept, and how does it differ from other anti-VEGF drugs? (2:42)
4. How does the Treat-and-Extend (T&E) regimen differ from a monthly treatment regimen? Are there any benefits of T&E compared with monthly treatment? (3:20)
5. How important is the dosing frequency for real-world AMD treatment from the point of view of both patients and clinicians? (4:11)
Speaker disclosures: Paul Mitchell is a speaker for Bayer.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.